Kissei Pharmaceutical Co., Ltd. announced that a new drug application for Silodosin, a novel drug for dysuria associated with benign prostatic hyperplasia (BPH), originally developed by Kissei Pharmaceutical Co., Ltd, and previously licensed out to Watson Pharmaceuticals, Inc. (U.S.), has been filed with [the] U.S. Food and Drug Administration (FDA).
JCN Network